ClinicalTrials.gg
Active, not recruitingNCT06805006i-StitchSSLFUpdated Nov 2, 2026

i-Stitch for Bilateral Sacrospinous Ligament Fixation (SSLF)

An observational study in Pelvic Organ Prolapse and Genital Prolapse, sponsored by A.M.I. Agency for Medical Innovations GmbH. Active, not recruiting at 1 site in Germany. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by A.M.I. Agency for Medical Innovations GmbH · Observational

How we know

Updated Nov 2, 2026Now Active, not recruitingPrimary outcomes revised+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Pelvic Organ Prolapse with a site in Germany — 4 open to participants now, 6 under way, none of them phase 3. Pelvic Organ Prolapse · Germany.

Planned enrollment
8th of 14
100 · median 113
Started
2025
with 1 other
Observational
14 of 19
2 open now
Registered
16th of 19
by date
Lead sponsor
4 of 19
A.M.I. Agency for Medical Innovations GmbH

Among the 19 studies in Pelvic Organ Prolapse with a site in Germany, this one is the 8th largest by planned enrollment of the 14 observational ones that give a count, is one of 2 that started in 2025, is one of 14 observational ones, and was the 16th registered.

Pelvic Organ Prolapse

522 studies on the registry are indexed under Pelvic Organ Prolapse; 81 are open to participants now.

Browse Pelvic Organ Prolapse studies →

Open to participants now

4 of the 19 studies in Pelvic Organ Prolapse with a site in Germany are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 53 Pelvic Organ Prolapse studies recruiting now, 31 (58%) set no upper age limit and 10 (19%) stop at 75 or younger; 2 take children under 18; 14 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Pelvic Organ Prolapse with a site in Germany, or all of them as a file.
02

Study summary

The purpose of the clinical investigation is to generate clinical data to substantiate the safety and performance of the i-Stitch device for bilateral sacrospinous ligament fixation (SSLF) in pelvic organ prolapse (POP) repair.

Read the detailed description

The i-Stitch instrument is a reusable instrument for attaching sutures to tissue with or without surgical mesh implants in urogynaecology. It is used together with the i-Stitch loading units. The use of i-Stitch for the fixation of surgical urogynaecological mesh implants (e.g. BSC Mesh, InGYNious) has already been proven in several studies.

The aim of the present retrospective study is to generate clinical data to show the safety and performance of the i-Stitch instrument in bilateral sacrospinous ligament fixation (SSLF) without the use of a surgical mesh.

03

Conditions studied

  • Pelvic Organ Prolapse
  • Genital Prolapse

Browse trials for

Keywords

  • bilateral sacrospinous ligament fixation
  • suture attachment medical device
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with symptomatic pelvic organ prolapse indicated for a surgical intervention.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Surgery for POP
  • SSLF with usage of i-Stitch device (\& i-Stitch Loading Units)
  • Concomitant procedures are allowed
  • Women minimum 18 years old
  • Written for surgery

Exclusion criteria

Exclusion Criteria:

  • infection (active or latent)
  • allergies to the materials used
  • benign or malignant changes
  • anticoagulation disorders
  • connective tissue disorders
  • any uterus pathologies
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • DeviceSSLF

    Bilateral sacrospinous ligament fixation with i-Stitch device

06

What researchers measure

Primary outcomes

  1. Change in Pelvic Floor Function Score (German Pelvic Floor Questionnaire)

    German Pelvic Floor Questionnaire ("Deutscher Beckenboden-Fragebogen"): Validated patient-reported outcome measure assessing pelvic floor symptoms and their impact on quality of life. The questionnaire evaluates the domains of bladder function, bowel function, pelvic organ prolapse, and sexual function. Scores are calculated according to the validated scoring system. Scoring (domain scores from 0 to 10): higher scores indicate greater symptom burden and worse pelvic floor dysfunction.

    Time frame: 12 months

  2. Change in Pelvic Floor Function Score (German Pelvic Floor Questionnaire)

    German Pelvic Floor Questionnaire ("Deutscher Beckenboden-Fragebogen"): Validated patient-reported outcome measure assessing pelvic floor symptoms and their impact on quality of life. The questionnaire evaluates the domains of bladder function, bowel function, pelvic organ prolapse, and sexual function. Scores are calculated according to the validated scoring system. Scoring (domain scores from 0 to 10): higher scores indicate greater symptom burden and worse pelvic floor dysfunction.

    Time frame: 3 months

Secondary outcomes

  1. Change in Urinary Incontinence Severity and Quality of Life (ICIQ-UI SF)

    The ICIQ-UI SF is a validated patient-reported outcome measure that assesses the frequency, severity, and impact of urinary incontinence on daily life. Scoring: The total score ranges from 0 to 21, with higher scores indicating more severe urinary incontinence symptoms and greater impact on quality of life (worse outcome).

    Time frame: 12 months

  2. Percentage of Postoperative Complications

    Complications in women undergoing bilateral SSLF using the i-Stitch

    Time frame: 12 months

  3. Anatomical outcome (POP-Q)

    Anatomical outcome assessed using the Pelvic Organ Prolapse Quantification (POP-Q) system. Objective anatomical failure is defined as recurrent pelvic organ prolapse in any vaginal compartment (anterior, apical, or posterior) identified at the 12-month follow-up examination.

    Time frame: 12 months

07

Study locations

1 site
  • Isar Kliniken GmbH
    Munich, Bavaria 80331, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Jan 2025 to primary completion in Jul 2026, 18 months.

Completion moved once since we started tracking on Sep 25, 2026: Oct 2026 → Dec 2026, on Oct 30, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2025
First posted
Feb 3, 2025
StartActual
Jan 1, 2025
Primary completionActual
Jul 30, 2026
CompletionEst.
Dec 31, 2026was Oct 2026
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Enrolling by invitation→Active, not recruiting
changed Oct 30, 2026
Study completion
Oct 31, 2026→Dec 31, 2026
Oct 30, 2026
Primary outcomes
2 added, 2 removed
What changed in the outcomes
  • AddedChange in Pelvic Floor Function Score (German Pelvic Floor Questionnaire)Time frame: 12 months
  • AddedChange in Pelvic Floor Function Score (German Pelvic Floor Questionnaire)Time frame: 3 months
  • RemovedSubjective outcomeTime frame: 12 months
  • RemovedSubjective outcomeTime frame: 3 months
Nov 2, 2026
Secondary outcomes
2 edited, 1 description edited
What changed in the outcomes
  • EditedChange in Urinary Incontinence Severity and Quality of lifeLife (ICIQ-UI SF)Time frame: 12 months
  • EditedPercentage of Postoperative complicationsComplicationsTime frame: 12 months
  • DescriptionAnatomical outcome (POP-Q): how it is measured was reworded
Nov 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Primary outcomes 2 added, 2 removed
    What changed in the outcomes
    • AddedChange in Pelvic Floor Function Score (German Pelvic Floor Questionnaire)Time frame: 12 months
    • AddedChange in Pelvic Floor Function Score (German Pelvic Floor Questionnaire)Time frame: 3 months
    • RemovedSubjective outcomeTime frame: 12 months
    • RemovedSubjective outcomeTime frame: 3 months
    Secondary outcomes 2 edited, 1 description edited
    What changed in the outcomes
    • EditedChange in Urinary Incontinence Severity and Quality of lifeLife (ICIQ-UI SF)Time frame: 12 months
    • EditedPercentage of Postoperative complicationsComplicationsTime frame: 12 months
    • DescriptionAnatomical outcome (POP-Q): how it is measured was reworded
  2. Oct 30, 2026
    Enrolling by invitation→Active, not recruiting
    Study completion Oct 31, 2026→Dec 31, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06805006
Lead sponsor
A.M.I. Agency for Medical Innovations GmbH
Responsible party
Sponsor
First posted
Feb 3, 2025
Start date
Jan 1, 2025
Primary completion
Jul 30, 2026
Completion
Dec 31, 2026 (estimated)
Last update
Nov 2, 2026

Study contacts

Ursula Peschers, Prof. Dr.
principal investigator · ISAR Klinikum Munich

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion